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The interaction between vaginal
microbiota, cervical length, and vaginal
progesterone treatment for preterm birth
risk
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Abstract
Background: Preterm birth is the primary cause of infant death worldwide. A short cervix in the second trimester of
pregnancy is a risk factor for preterm birth. In specific patient cohorts, vaginal progesterone reduces this risk. Using 16S
rRNA gene sequencing, we undertook a prospective study in women at risk of preterm birth (n = 161) to assess (1) the
relationship between vaginal microbiota and cervical length in the second trimester and preterm birth risk and (2) the
impact of vaginal progesterone on vaginal bacterial communities in women with a short cervix.
Results: Lactobacillus iners dominance at 16 weeks of gestation was significantly associated with both a short cervix
<25 mm (n = 15, P < 0.05) and preterm birth <34+0 weeks (n = 18; P < 0.01; 69% PPV). In contrast, Lactobacillus crispatus
dominance was highly predictive of term birth (n = 127, 98% PPV). Cervical shortening and preterm birth were not
associated with vaginal dysbiosis. A longitudinal characterization of vaginal microbiota (<18, 22, 28, and 34 weeks) was
then undertaken in women receiving vaginal progesterone (400 mg/OD, n = 25) versus controls (n = 42). Progesterone
did not alter vaginal bacterial community structure nor reduce L. iners-associated preterm birth (<34 weeks).
Conclusions: L. iners dominance of the vaginal microbiota at 16 weeks of gestation is a risk factor for preterm birth,
whereas L. crispatus dominance is protective against preterm birth. Vaginal progesterone does not appear to impact
the pregnancy vaginal microbiota. Patients and clinicians who may be concerned about “infection risk” associated with
the use of a vaginal pessary during high-risk pregnancy can be reassured.
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Background
Preterm birth before 37 weeks of gestation is now the
leading cause of death among children under the age of
five [1]. An estimated 15 million babies are born preterm
each year, and in the USA alone, the annual healthcare
costs associated with those babies that survive is in ex-
cess of $25 billion [2]. Ascending bacterial infection
from the vagina through the cervix into the uterine cav-
ity is considered to be a major cause of spontaneous
preterm birth [3–5]. Maternal host-vaginal microbial in-
teractions throughout pregnancy are likely to play a fun-
damental role in reproductive health outcomes. Unlike
other body sites where high bacterial diversity is consid-
ered beneficial to health [6, 7], a healthy vaginal commu-
nity structure in pregnancy is dominated by only one, or
a few, Lactobacillus species [8, 9]. These species provide
protection against pathobiont colonization through
excretion of lactic acid and production of antimicrobial
compounds [10]. Assessment of vaginal microbial com-
munity structure can be performed using a variety of
next generation sequencing and PCR-based platforms.
The resulting data is typically analyzed using multivari-
ate clustering approaches that permit comparison of
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individual taxa or community compositions [11–13]. A
commonly used classification scheme involves hierarch-
ical clustering analysis of 16S rRNA gene sequencing
data into community state types (CSTs) as first described
by Ravel and colleagues [13]. CSTs are typically domi-
nated by one of four Lactobacillus species; Lactobacillus
crispatus (CST I), Lactobacillus gasseri (CST II),
Lactobacillus iners (CST III), and Lactobacillus jensenii
(CST V). CST IV describes microbial communities
largely devoid of Lactobacillus species and enriched
mainly in anaerobic bacteria (CST IV).
The composition of vaginal CSTs appears to be influ-
enced by endogenous hormones, fluctuating with men-
ses [14], the use of oral contraceptives [15] and onset of
menopause [16], and estrogen supplementation in post-
menopausal states [17]. In pregnancy, elevated concen-
trations of circulating estrogen drive glycogen accumula-
tion in the vaginal epithelium, which is broken down by
host α-amylase to complex sugar products such as mal-
totetraose, maltotriose, and maltose providing carbon
sources preferentially utilized by Lactobacillus species
[18]. This substrate availability leads to increased Lacto-
bacillus species abundance and stability with advancing
gestation and a decline in the number of women harbor-
ing microbial communities void of lactobacilli, with a
dramatic change to reduced Lactobacillus dominance
and increased diversity following estrogen withdrawal in
the post-partum period [8, 19]. There is an association
between Lactobacillus spp. depletion and vaginal dysbio-
sis and poor pregnancy outcomes including preterm
birth [19] and late miscarriage [20], which appears to be
patient cohort dependent [9]. Thus, the interplay be-
tween hormonal and metabolic signaling at the vaginal
mucosa interface may act as a protective mechanism for
the immuno-modulated pregnant mother, against expos-
ure to pathogenic bacteria [21]. This may influence not
only immediate pregnancy outcomes but also longer im-
munological health in the neonate such as allergy and
asthma [22, 23]. This vaginal dysbiosis is present in
between 2 and 27% of the population in pregnancy but
does not always appear to be pathogenic [8, 24]. Recent
evidence implicates L. iners dominance rather than
dysbiosis for preterm birth risk in pregnancy [25]. L.
iners is a vaginal commensal that has relatively recently
been shown to be associated with dysbiosis [26, 27] and
has been suggested as marker of microbial imbalance
leading to BV [28].
The cervix serves as both a mechanical and chemical
barrier to ascending bacteria [29]. Premature cervical
ripening, a prerequisite for the expulsion of the fetus,
may be triggered by exposure of the amniotic cavity to
pathogenic bacteria ascending from the vagina [30],
which drives a pro-inflammatory cytokine response, trig-
gering prostaglandin release, and untimely cervical
remodeling, softening, and dilation [31]. Premature cer-
vical ripening is detectable by transvaginal ultrasound
(TVS) several weeks prior to the onset of the clinical
symptoms of preterm labor. Second trimester transvagi-
nal cervical length measurements are considered a
reliable and predictive tool for preterm birth and are fre-
quently used for preterm birth surveillance [32]. Preg-
nant women with a short cervix, <25 mm before
24 weeks of gestation are considered at highest risk of
preterm birth [33]. Early diagnosis of these pregnancies
enables timely and targeted intervention by either
cervical cerclage or vaginal progesterone therapy [34].
While both prevention strategies display comparable
efficacy [35], progesterone supplementation is increas-
ingly used as it negates the surgical risks associated with
cerclage insertion such as maternal pyrexia, vaginal
infection, bleeding, and subsequent requirement for
cesarean section [36, 37] and has not been associated
with any adverse neonatal effects [38, 39].
The mechanism of action of vaginal progesterone in
the prevention of preterm birth involves its capacity to
promote anti-inflammatory and pro-relaxant pathways
in the uterus thereby reducing uterine contractility [40–
43]. Endogenous progesterone is thought to largely exert
anti-inflammatory downstream effects via progesterone
receptor B-dominant signaling [43] to inhibit nitric
oxide, prostaglandin, and cytokine production [41, 42].
This ultimately reduces myometrial contractility thereby
inhibiting premature onset of labor [40]. Progesterone
also exerts a quiescent effect on the cervix by limiting
prostaglandin-induced collagenous remodeling of the
cervical fibroblast [44–46]. Progesterone supplementa-
tion is therefore prescribed primarily for its systemic
anti-inflammatory actions to maintain myometrial and
cervical quiescence in high-risk pregnancies. In clinical
studies, vaginal progesterone has been shown to attenu-
ate the rate of cervical shortening [47, 48], but its effi-
cacy in preterm birth prevention is cervical-length
dependent [48–51] with most benefit observed in high-
risk pregnancies with a short cervix <25 mm [35]. Ad-
ministration of vaginal progesterone to women with a
long cervix has not been shown to improve pregnancy
outcome [51]. Studies on the impact of progesterone on
the composition of the vagina microbiota are limited. In
non-pregnant women, Borgdorff et al. [52] found that
both injectable progestin contraception and combined
oral contraception (progestin and estrogen) do not
significantly alter vaginal microbiota, but may increase
the risk of HIV transmission [53]. It is has been hypoth-
esized that this susceptibility relates to a progesterone-
induced modulation of the local inflammatory immune
response to infection or alternately thinning of the vagi-
nal epithelial barrier [54]. The impact of vaginal proges-
terone pessaries on the composition of vaginal microbial
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communities in pregnancies at risk of preterm birth is
unknown.
We hypothesized that progesterone supplementation
would promote Lactobacillus spp. dominance and stabil-
ity, given progesterone’s anti-inflammatory properties,
and efficacy for preterm birth prevention. We therefore
undertook a prospective study in women at high-risk of
preterm birth to assess (1) the relationship between
vaginal microbiota in the second trimester and the risk
of preterm birth and (2) the impact of vaginal progester-
one therapy on the vaginal microbiota in women with a
short cervix.
Methods
The study was approved by NHS National Research
Ethics Service (NRES) Committee London - City and
East (REC 12/LO/2003), and all participants provided
written, informed consent at enrolment. A workflow of
the study is provided in Additional file 1.
Patient details and sample collection for cross-sectional
recruitment
To investigate the association between the vaginal
microbiome, cervical length, and preterm birth outcome,
a cross-sectional cohort of singleton pregnancies at
higher than normal risk of preterm birth (due to a his-
tory of previous spontaneous preterm birth <37 weeks+0
days) were prospectively recruited from the preterm sur-
veillance clinics at two tertiary London maternity units
between January 2013 and August 2014. At initial at-
tendance of preterm surveillance clinics at 16 weeks of
gestation, cervico-vaginal fluid was sampled from the
posterior fornix under direct visualization, using a BBL™
CultureSwab™ MaxV Liquid Amies swab (Becton,
Dickinson and Company, Oxford, UK). The vaginal
swabs were placed immediately on ice before being
transferred and stored at −80 °C within 5 min of collec-
tion. A cervical length (CL) measurement was taken by
transvaginal scan (TVS) in supine position, with an
empty bladder, taking care to avoid undue pressure on
the cervix. Metadata collected included gestation age at
sampling, subsequent interventions for preterm birth,
gestation at birth, BMI, ethnicity, and antibiotics within
the week preceding sampling. Participation in this study
did not influence subsequent clinical care or dictate pre-
ventative interventions (cervical cerclage or vaginal
progesterone supplementation) for preterm birth risk.
For the duration of the study, both units employed a
policy of CL screening every 3 weeks until 25 weeks,
with the indication for intervention being a CL <25 mm
at TVS measured at ≤23+6 weeks gestation. In this
cross-sectional arm of the study, the choice of interven-
tion for a short cervix (cerclage or progesterone) was at
the discretion of the attending clinician.
Longitudinal sampling following progesterone
intervention
A longitudinal study was undertaken in a new pregnancy
cohort to assess the effect of progesterone therapy on
pregnancy with a short cervix. Women with a prior pre-
term birth <37 weeks were prospectively recruited from
the same preterm surveillance clinics. At initial screen-
ing ≤18 weeks, all women underwent vaginal swab
sampling for 16S rRNA gene sequencing, followed by
CL measurement at TVS, as previously described. Based
on CL measurement, women were then allocated into
one of two groups. Women with a short cervix <25 mm
were treated with vaginal progesterone 400 mg OD at
night to continue until 34 completed weeks gestation.
Women with a CL ≥25 mm were used as controls and
did not receive progesterone or cerclage for the remain-
der of their pregnancy. Both progesterone and control
groups were recruited at ≤18 weeks, and vaginal swab
samples were collected longitudinally at 22, 28, and
34 weeks of gestation.
Eligibility criteria for participation in both cross-
sectional and longitudinal studies included women with
a singleton pregnancy and a prior spontaneous preterm
birth <37 weeks+0 days, who had not undergone CL
screening or received either progesterone or cerclage
intervention prior to recruitment. Exclusion criteria in-
cluded multiple pregnancy, preterm pre-labor rupture of
membranes (PPROM), iatrogenic preterm birth, HIV
positive women, and women who had had sexual inter-
course or vaginal bleeding in the preceding 48 h. In the
longitudinal study, any women receiving cervical cerc-
lage in either the progesterone or control groups were
excluded as this may adversely impact on vaginal micro-
biota [37].
DNA extraction and 16S rRNA gene sequencing
DNA extraction from BBL™ CultureSwab™ was per-
formed as previously described [8]. Forward and reverse
fusion primers were used to amplify the V1-V3 hyper-
variable regions of 16S rRNA genes. The forward primer
was made up of an Illumina i5 adapter (5′-3′) (AATGA-
TACGGCGACCACCGAGATCTACAC), 8 bp barcode,
primer pad (forward: TATGGTAATT), and the 28F-
GAGTTTGATCNTGGCTCAG primer [55]. The reverse
fusion primer consisted of an (5′-3′) Illumina i7 adapter
(CAAGCAGAAGACGGCATACGAGAT), 8 bp barcode,
primer pad (reverse: AGTCAGTCAG), and the reverse
primer (519R-GTNTTACNGCGGCKGCTG). Sequen-
cing was performed on an Illumina MiSeq platform
(Illumina, Inc. San Diego, California). Sequence data was
processed and analyzed using the MiSeq SOP Pipeline of
the Mothur package [56] with the Silva bacterial data-
base (www.arb-silva.de/) used for sequence alignment.
Sequence classification was performed using the RDP
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database reference sequence files and the Wang method
[57] and taxonomy assignments determined using the
RDP MultiClassifier script and USEARCH with 16S
rRNA gene sequences from the cultured representatives
from the RDP database [58] for species level taxonomies.
Data was re-sampled and normalized to the lowest read
count in Mothur (n = 725) [59].
Statistical analyses
Examination of statistical differences between vaginal
microbiota was performed using the Statistical Analysis
of Metagenomic Profiles (STAMP) software package
[60]. To classify vaginal bacterial communities into com-
munity state types (CSTs), hierarchical clustering ana-
lysis (HCA) species taxonomy was performed using
ward linkage with a clustering density threshold of 0.75.
Samples were classified into five CSTs; I (L. crispatus), II
(L. gasseri), III (L. iners), IV (mixed bacterial species),
and V (L. jensenii) as described by Ravel et al. [13].
Cross-sectional cohort
In the cross-sectional cohort, a total number of species
observed and the Shannon index of alpha diversity were
calculated and compared across gestation at birth: <34
+0 weeks, 34+0 to 36+6 weeks, and ≥37+0 weeks, using a
2-way ANOVA.
Examination of the relationship between vaginal bac-
terial communities (or CSTs) and cervical length or pre-
term birth was assessed using a Fisher exact test as to
provide an exact, robust P value that is less sensitive to
small sample sizes than alternative approaches such as
Chi-squared (reference). Fisher’s exact test was also used
to examine individual CST assignments (in 5 × 2 contin-
gency tables for cervical length and requirement for fu-
ture interventions and 3 × 25 contingency tables for
birth gestation and ethnicity). Gehan-Breslow-Wilcoxon
test was used to compare pregnancy survival (duration
of gestation) for CST I compared to CST III [61].
A logistic mixed-effects regression analysis incorporat-
ing gestational age at sample, maternal age, and BMI as
fixed effects and ethnicity as a random effect was per-
formed to assess the relationship between pregnancy
outcome (birth <34 and >34 weeks) and CSTs as well as
individual species abundance. Analyses were performed
in R using ANOVA and the “glm” (generalized linear
model) R function to analyze the table of deviance for
CSTs and for individual species (present in >5% of sam-
ples). Species abundances were log-transformed, ad-
justed for confounders, and false discovery rate
adjustment (Benjamini-Hochberg) was applied to correct
P values for each analysis [62].
Accuracy parameters, sensitivity (sens), specificity
(spec), positive predictive values (PPV), and negative
predictive values (NPV) were calculated for the
prediction of preterm birth <34+0 weeks according to
CST classification at 16-week sampling.
Longitudinal cohort
A linear mixed-effects model incorporating gestational
age, maternal age, BMI, ethnicity (Asian, Black, or Cau-
casian), and cohort (progesterone with short cervix ver-
sus control with normal cervix) as fixed-effects and the
anonymized patient ID as uncorrelated random-effect
was used to assess the impact of progesterone interven-
tion on CST distribution and relative abundance in spe-
cies present in >5% of all samples. The contributions of
fixed-effects terms (P value and F statistics) were calcu-
lated using ANOVA with Satterthwaite approximation
for degrees of freedom. For each fixed-effects term, a
false discovery rate adjustment (Benjamin-Hochberg)
was applied to correct P values. All data and computa-
tional approaches used for this study are provided in
additional information (Additional files 2, 3, 4, 5, and 6).
Results
Cross-sectional study patient cohort demographics
A total of 161 pregnant women attending prematurity
surveillance clinics for their first appointment (mean 16
+6 weeks gestation, Table 1) consented to a vaginal swab
followed by a transvaginal scan for cervical length meas-
urement. Spontaneous preterm birth <37 weeks oc-
curred in 34 women (21%) (mean 32+6 weeks, SD ± 3
+6 weeks, range 24+4–36+6 weeks). Rates of preterm birth
<37+0 weeks were higher in Black women (37%, 11/30)
than Caucasians (17%, 18/104) and Asians (19%, 5/27; P
< 0.05). Subsequent cervical shortening to below 25 mm
occurred in 66% (91/161), all of whom went on to re-
ceive an intervention (ultrasound indicated cervical cerc-
lage, n = 71 or vaginal progesterone, n = 20).
The vaginal microbiome at 16 weeks in high-risk
pregnancy
Using hierarchical clustering analysis (HCA) of normal-
ized genera taxonomy read counts, vaginal swab samples
were classified into three categories; normal (>90%
Lactobacillus spp., 147/161, 91%), intermediate (50–90%
Lactobacillus spp., 5/161, 3%), and dysbiotic (<10%
Lactobacillus spp., 9/161, 6%; Additional file 7A). No re-
lationship was observed between genera level structure
and subsequent gestational age at delivery. Dominance
of Lactobacillus species occurred in equal proportions of
patients experiencing preterm <37 weeks (31/34; 91%)
or term birth (116/127; 91%). Of those women delivering
preterm, 3/34 (9%) harbored a dysbiotic or intermediate
microbiome at 16 weeks compared to 6/127 (5%) who
delivered at term. Consistent with these findings, mea-
surements of species richness (total number of species
observed; Additional file 7B) and alpha diversity
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(Shannon index; Additional file 7C) at 16 weeks were com-
parable between women experiencing term (≥37+0 weeks,
n = 127), late preterm (34+0–36+6 weeks, n = 16), and early
preterm (<34+0 weeks, n = 18) delivery.
Hierarchical clustering of species data permitted clas-
sification of samples into community state types (CSTs):
I (L. crispatus), II (L. gasseri), III (L. iners), IV (diverse
species), and V (L. jensenii) (Fig. 1a). The most prevalent
CST observed in the patient cohort was CST I (L. cris-
patus, 40%), followed by CST III, (L. iners, 34%), CST II
(L. gasseri, 10%); CST V (L. jensenii, 9%), and CST IV
(diverse, 6%; Table 2). L. crispatus (CST I) was most
abundant among Caucasian women (P = 0.008), while
Black women had greater numbers of CST III (L. iners;
P = 0.049 and CST IV (P = 0.033) (Fisher’s exact, Table 2).
Short CL <25 mm was significantly associated with L.
iners (CST III) dominance (9/15, 60%) compared to
those women with a CL >25 mm (45/101, 31%; P = 0.04;
Fisher’s exact, Fig. 1b).
The association of the vaginal microbiome at 16 weeks of
gestation and risk of preterm birth
Major differences were detected in vaginal microbial
communities at 16 weeks in women subsequently
delivering early preterm (<34+0 weeks) compared those
delivering late preterm (34+0 to 36+6 weeks) or at term
(>37+0 weeks) (Fig. 1b, Table 2). Specifically, an L. iners-
dominated microbiome was significantly over-
represented in women delivering <34+0 weeks (67%)
compared to late preterm (31%) and term (29%; P =
0.003, Fisher’s exact). In contrast, L. crispatus dominance
associated with subsequent term birth (46 vs. 11% early
preterm birth; P = 0.009, Fisher’s exact, Fig. 1c, Table 2),
and comparatively longer duration of pregnancy than L.
iners Fig. 1d. A logistic regression mixed-effects model
demonstrated that the association between gestation at
birth and CST at 16 weeks persisted after accounting for
ethnicity, maternal age, BMI, and gestation at sampling
(P = 0.04; ANOVA; Additional file 8). When individual
species were assessed by mixed-effects modeling follow-
ing correction for potential confounders, both L. crispa-
tus and L. iners were significantly correlated with birth
outcome with L. crispatus positively associated with
delivery >34 weeks (P = 0.009, q = 0.048) and L. iners
positively associated with delivery <34 weeks (P = 0.001,
q = 0.006; Additional file 9).
The analysis of outcomes stratified by ethnicity did not
identify a significant difference between groups although
this may be due to relatively small sample sizes. The ma-
jority of women delivering >34 weeks with L. crispatus
dominance (CST I) were Caucasian (Caucasian 50/95,
53%, Asian 7/23, 30%, and Black women 6/25, 24%), but
Table 1 Patient demographics for a cross-section of 161 participants
Term birth >37 weeks Preterm birth <37 weeks Total
n/N (%) 127/161 (79%) 34/161 (21%) 161/161 (100%)
BMI
Mean ± SD (range) 24.3 ± 4.4 (18–48) 24.3 ± 4.4 (18.4–35) 24.3 ± 4.4 (18–48)
Ethnicity, n/N (%)
Caucasian 86/127 (68%) 18/34 (53%) 104/161 (65%)
Asian 22/127 (17%) 5/34 (15%) 27/161 (17%)
Black 19/127 (15%) 11/34 (32%)* 30/161 (19%)
Smoker, n/N (%) 8/127 (6%) 3/34 (9%) 11/161 (7%)
Gestation at sample (weeks)
Mean ± SD (range) 17+0 ± 1.0 (13+1–18+4) 16+4 ± 1.4 (12+1–18+4) 16+6 ± 1.1 (12+1–18+4)
Cervical length (mm)
Mean ± SD (range) 32.5 ± 1.0 (18–50) 30.6 ± 6.4 (10–40) 32 ± 5.6 (10–50)
Intervention n/N (%)
No intervention 60/127 (47%) 10/32 (29%) 70/161 (43%)
Cerclage 51/127 (40%) 20/32 (59%) 71/161 (44%)
Progesterone 16/127 (13%) 4/32 (12%) 20/161 (12%)
Gestation at delivery, n/N (%)
Early PTB, <34+0 weeks na 18/34 (53%) 18/161 (11%)
Late PTB, 34+0 to <37+0 weeks na 16/34 (47%) 16/161 (10%)
Term, ≥37+0 weeks 127/127 (100%) na 127/161 (79%)
PTB preterm birth, na not applicable
*P < 0.05 Fisher’s exact term vs. preterm birth groups
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this was not significant. In those women delivering <34
with L. iners dominance (CST III), similar proportions
were represented across ethnic groups (Caucasian 6/9,
67%, Asian 3/4, 75%, and Black women 3/5, 60%;
Additional file 10).
Calculation of predictive accuracies for preterm birth
using CST assignments at 16 weeks provided sensitivity
and specificity values comparable to screening using cer-
vical length [32]: L. iners dominance predicted preterm
birth <34+0 weeks with 67% sensitivity and 71% specifi-
city (Table 3). While its absence provided a 94% negative
predictive value (NPV), the PPV of L. iners dominance
for preterm birth <34 weeks was 22%. High relative L.
crispatus abundance was strongly predictive of birth
>34 weeks gestation (89% specificity and 97% PPV;
Table 3).
Effect of progesterone intervention on vaginal microbial
communities in high-risk pregnancy
Given the significant association between vaginal micro-
bial composition at 16 weeks and cervical length and/or
subsequent preterm birth <34+0 weeks, we next con-
ducted a longitudinal study of the vaginal microbiome in
women receiving vaginal progesterone supplementation
for a short cervix (<25 mm). A total of 67 pregnant
women were eligible and consented to recruitment, of
Fig. 1 L. iners dominance is associated with a short cervix and preterm birth risk while L. crispatus is protective. a Heatmap of vaginal species data
correlated community state types of samples (n = 161) with ethnicity, cervical length <25 mm, subsequent cerclage or progesterone intervention,
and gestation at birth. b A short cervix <25 mm at 16 weeks was associated with a higher prevalence of L. iners (9/15, 60%) than longer cervical
length (45/146, 31%, P = 0.04, two-tailed Fisher’s exact). c L. iners dominance was associated with early preterm birth <34+0 weeks (12/18, 67%),
but not late preterm birth, 34+0 to 36+6 weeks (5/16, 31%) or term birth (37/127, 29%, P = 0.003). A greater proportion of term births had L.
crispatus dominance at 16 weeks (63/127, 46%) than both late preterm (5/16, 31%) and early preterm births <34+0 weeks (2/18, 11%; P = 0.009;
Fisher’s exact). d A Kaplan-Meier survival curve demonstrated that L. iners (n = 54) dominance at 16 weeks is associated with earlier gestation at
delivery than a microbiome dominated by L. crispatus (n = 65, P = 0.02; Gehan-Breslow-Wilcoxon test)
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which 25 were found to have a short CL <25 mm and
received progesterone until 34 weeks of gestation. The
remaining 42 women did not experience cervical short-
ening or receive any subsequent preventative interven-
tion, and hence were used as controls. Demographics of
the two groups were comparable although, as per study
design, the mean CL at commencement of progesterone
was significantly lower in the “short CL” than the “nor-
mal” control group (22 vs. 32 mm, P < 0.05) at compar-
able screening gestations (15+5 vs. 15+0, respectively;
Table 4). Respective rates of preterm birth (<37 weeks)
were higher in the progesterone (32%, 8/25) versus
control groups (5%, 2/42; P = 0.004). A total of 234 high
vaginal samples were collected from longitudinal follow-
up (22, 28, and 34 weeks) at matched gestational ages
among groups (Additional file 11).
The distribution of CSTs in the progesterone and con-
trol groups at each sampling time point is provided in
Additional file 12. Prior to progesterone intervention, no
significant difference in the distribution of CSTs between
to the two patient cohorts was observed (Fig. 2;
Additional file 12). Vaginal progesterone supplementa-
tion had no effect upon vaginal bacterial community
state structure throughout pregnancy (Fig. 2a) nor were
species richness or alpha diversity measurements altered
(Fig. 2b, c). Progesterone supplementation did not sig-
nificantly impact on mean relative abundance of L. iners
or L. crispatus with advancing gestation when compared
to controls (Fig. 2d, c; Additional file 13).
The dynamics of individual vaginal CSTs during preg-
nancy were then longitudinally assessed in both proges-
terone and control cohorts (Fig. 3). Regardless of
intervention, a L. crispatus (CST I)-dominated micro-
biome was associated with high stability throughout
pregnancy with 92% (24/26) of women maintaining L.
crispatus dominance across all sampling time points. In
contrast, significantly lower stability was observed in the
23 women exhibiting a L. iners-dominated microbiome
at the first sampling with 17 (74%) of these women ex-
periencing a shift to an alternative CST at some stage
during their pregnancy (P < 0.0001). Similar levels of
CST-shifting were observed in those women receiving
vaginal supplementation (9/25; 36%) and control
patients (10/43; 23%) (P = 0.3).
When gestational age at sampling, maternal age, BMI,
ethnicity, and cohort were incorporated into a linear
mixed-effects model, progesterone treatment did not
have a significant impact upon CSTs apart from CST II;
however, this difference did not withstand multiple test-
ing correction (Additional file 14). When further
assessed by relative abundance of individual species,
there were no significant differences in proportions of L.
gasseri, or any other species in the control compared to
progesterone cohorts (Additional file 15).
Table 2 Distribution of community state types according to ethnicity and gestation at birth
CST, Species
Total population CST I, L. crispatus CST II, L. gasseri CST III, L. iners CST IV, diverse species CST V, L. jensenii
n/N (%) 161 (100%) 65/161 (40%) 17/161 (11%) 54/161 (34%) 11/161 (7%) 14/161 (9%)
Ethnicity
Caucasian 104/161 (65%) 52/104 (50%)* 13/104 (13%) 26/104 (25%) 5/104 (5%) 8/104 (8%)
Asian 27/161 (17%) 7/27 (26%) 3/27 (11%) 13/27 (48%)* 1/27 (4%) 3/27 (11%)
Black 30/161 (19%) 6/30 (20%) 1/30 (3%) 15/30 (50%)* 5/30 (17%)* 3/30 (10%)
Gestation at birth
<34 weeks 18/161 (11%) 2/18 (11%)** 1/18 (6%) 12/18 (67%)** 1/18 (6%) 2/18 (11%)
34–37 weeks 16/161 (10%) 5/16 (31%) 2/16 (13%) 5/16 (31%) 2/16 (13%) 2/16 (13%)
>37 weeks 127/161 (79%) 58/127 (46%) 14/127 (11%) 37/127 (29%) 8/127 (6%) 10/127 (8%)
CST community state type based on ward HCA of species data
*P < 0.05, **P < 0.01; for comparison of birth <34 vs. >34 weeks, two-tailed Fisher’s exact
Table 3 Predictive accuracies of microbial species dominance at 16 weeks for gestation <34 weeks
CST Species Preterm birth <34 weeks Birth >34 weeks
Sens/DR (%) Spec (%) PPV (%) NPV (%) Sens/DR (%) Spec (%) PPV (%) NPV (%)
I L. crispatus 11 56 3 83 44 89 97 17
II L. gasseri 6 89 6 88 11 94 94 12
III L. iners 67 71 22 94 29 33 78 6
IV Diverse 6 93 9 89 7 94 91 11
V L. jensenii 11 92 14 89 8 89 86 11
CST community state type based on ward HCA of species data, Sens/DR sensitivity or detection rate, Spec specificity, PPV/NPV positive/negative predictive values
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In women receiving progesterone, marked differences
in the longitudinal CST distributions were observed in
women delivering <34 weeks compared to those deliver-
ing >34 weeks (Fig. 4). At 18 weeks of gestation, L. iners
dominance was observed in 100% (4/4) of women who
subsequently delivered <34 weeks of gestation compared
to 24% (5/21) in women delivering >34 weeks. At deliv-
ery, L. iners dominance was observed in 50% (2/4) at
22 weeks and 100% (4/4) at 28 weeks (Figs. 3 and 4).
Discussion
This study represents the largest next generation
sequencing-based analysis of vaginal microbiota in preg-
nancies at risk of preterm birth to date. We demonstrate
a significant association between L. iners dominance of
the vaginal microbiome at 16 weeks of gestation with
subsequent preterm birth and conversely show that L.
crispatus dominance correlates with reduced risk or pre-
term birth. Moreover, we show that the insertion of a
progesterone pessary for prevention of preterm birth has
no adverse impact on vaginal microbial communities.
A healthy vaginal microbiome in non-gravid and
gravid subjects is often described as being synonymous
with low bacterial diversity and Lactobacillus species
dominance [63–66]. Examination of vaginal microbiota
at the time of delivery using culture and/or microscopy-
based techniques has shown that Lactobacillus species
dominance is negatively associated with delivery before
37 weeks of gestation (odds ratio 0.2) whereas bacterial
dysbiosis is positively associated with preterm delivery
(odds ratio 2.3) [66]. Using similar methodology,
Donders and colleagues recently reported that a
lactobacilli-dominated vaginal microbiome in the first
trimester was associated with a 75% lower risk of deliv-
ery before 35 weeks of gestation (0.26; 95% confidence
interval (CI) 0.12–0.56] compared to women harboring
a vaginal microbiome void of Lactobacillus species (OR
2.4; 95% CI 1.2–4.8) [67]. Using culture-independent
characterization of vaginal bacterial communities in a
high-risk pregnant population, we show that the per-
ceived benefit of lactobacilli dominance in pregnancy is
species specific; L. crispatus is advantageous and associ-
ated with term delivery whereas L. iners is associated
with increased risk of preterm delivery. Furthermore, L.
iners is associated more specifically with a risk of early
(<34 weeks) rather than late (34–37 weeks) preterm
birth. High relative abundance of L. crispatus is highly
specific for term birth, with a false positive rate (1 speci-
ficity) of just 3% in our population of women at high risk
because of a previous preterm birth. In this population,
second trimester dominance of L. iners carries a 67% de-
tection rate (i.e., sensitivity) for preterm birth before
34 weeks; a screening sensitivity comparable to cervical
length, the current and primary screening tool used for
preterm birth surveillance [32, 68]. Consistent with our
findings, Petricevic and colleagues recently reported an
over-representation of L. iners dominance in vaginal
swab samples collected from 13 preterm births derived
from a low-risk cohort of 111 pregnancies, and none of
whom delivered before 33 weeks of gestation [25].
Table 4 Participant demographics for control and progesterone groups
High risk controls Progesterone Total
n/N (%) 42/67 (63%) 25/67(37%) 67/67 (100%)
Age, years
Mean ± SD (range) 32 ± 5.5 (21–40) 32 ± 3.9 (22–38) 32 ± 5.0 (21–40)
BMI
Mean ± SD (range) 24.7 ± 5.3 (19–48) 25.2 ± 4.7 (18.4–35) 24.9 ± 5.0 (18.4–48)
Ethnicity, n/N (%)
Caucasian 32/42 (76%) 18/25 (72%) 50/67 (75%)
Asian 4/42 (10%) 3/25 (12%) 7/67 (10%)
Black 6/42 (14%) 4/25 (16%) 10/67 (15%)
Smoker n/N (%) 2/42 (5%) 0/25 (0%) 2/67 (3%)
Screening for progesterone
GA (weeks), median, range 15+0 (12+1–18+2) 15+6 (12+0–18+6) 15+3 (12+0–18+6)
CL (mm), median, range 32 (26–43) 22 (13–25) (13–43)
Gestation at delivery, n/N (%)
Early PTB, <34+0 weeks 1/42 (2%) 4/25 (16%) 5/67 (7%)
Late PTB, 34+0 to <37+0 weeks 1/42 (2%) 4/25 (16%) 5/67 (7%)
Term, ≥37+0 weeks 40/42 (95%) 17/25 (68%) 57/67 (85%)
PTB preterm birth, GA gestational age, CL cervical length (mm)
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However, this study was limited by the use of denaturing
gradient gel electrophoresis (DGGE) for the
characterization of only major Lactobacillus species and
could not identify other pathobionts in the samples.
While our study reveals a clear relationship between
relative abundance of vaginal Lactobacillus species and
risk of subsequent preterm birth, our data indicate that
Lactobacillus spp. depletion or vaginal dysbiosis in the
second trimester does not appear to contribute to pre-
term birth risk. The role of early gestational vaginal dys-
biosis in the pathology of preterm birth is controversial.
In agreement with our findings, a recent longitudinal
analysis of the vaginal microbiome by Romero and col-
leagues in 18 women experiencing preterm birth
(<34 weeks gestation) reported no association between
preterm birth and vaginal microbial dysbiosis when com-
pared to controls experiencing term delivery (n = 72) [24].
However, in their study, 95% (17/18) of preterm birth
samples and 86% of control samples were collected from
African American women who exhibit a higher pregnant
and non-pregnant background prevalence of vaginal
dysbiosis (CST IV) [13, 24]. In contrast to these findings,
Digiulio and co-workers [19] reported, in a small yet
densely sampled cohort of women experiencing preterm
birth (n = 15), which vaginal bacterial diversity does correl-
ate with risk of preterm delivery [19]. The clinical rele-
vance of these findings however are difficult to establish
considering the small sample size and the heterogeneous
nature of the cohort; only five women delivered preterm
spontaneously and almost half delivered within 1 week of
term dates (>36 weeks+3/7 days).
Our presented data provide some suggestion that vagi-
nal microbiota in Black women may not play as an im-
portant contributory role to preterm birth pathogenesis
as Caucasians and Asians. We did not however have
sufficient power to demonstrate the significance of this,
but this may be worth examining in future studies.
In our study, we also observed a high rate of CST-
shifting in women with an L. iners-dominated micro-
biome in the second trimester compared to women with
an L. crispatus-dominated microbiome. L. iners has been
reported as an intermediary between lactobacilli
Fig. 2 Vaginal progesterone treatment does not alter structure of the vaginal microbiome. a Compared to controls (n = 42), progesterone
supplementation (n = 25) had no significant impact upon microbial community profiles with advancing gestation. Similarly, no effect of
progesterone treatment upon b the number of species observed or c the corresponding Shannon index of alpha diversity was observed (2-way
ANOVA). Fewer women requiring progesterone had a L. crispatus dominated microbiome compared to controls (8/25, 32 vs. 18/42, 43%, P = 0.4);
however, progesterone treatment was associated with increased relative L. crispatus abundance with advancing gestation. Advancing gestational
age from 18 to 34 weeks was not associated with a significant shift in mean relative abundance of L. iners (d) or L. crispatus (e) in either the
controls or progesterone groups (Kruskal-Wallis, Dunn’s multiple comparison)
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dominance and CST IV-associated states and is the pre-
dominant microbiome in peri-menopausal women as
they transition through to postmenopausal dominance
of anaerobic bacteria [16]. Interactions between L. iners
and the maternal host likely provides a vaginal mucosal
environment permissible to colonization by BV-
associated pathogens, a setting in which it tolerates co-
existence well [69, 70]. Unlike other Lactobacillus species,
L. iners also induces secretion of pro-inflammatory cyto-
kines when human vaginal epithelial cells are observed in
vitro, whereas L. crispatus does not [71, 72].
Other evidence for a role of bacterial dysbiosis in the
pathology of preterm birth includes the long recognized
association between bacterial vaginosis (BV) and in-
creased risk of preterm birth; however, evidence suggests
that screening and treating BV in pregnancy reduces
preterm delivery in certain cohorts [73], but not in
others [74]. We propose an alternate concept, which is
that it is the presence of L. iners that promotes risk of
early preterm birth, but because an L. iners-dominated
vaginal microbiome has less stability, there is a tendency
for transition to BV-associated CST-IV [69, 75]. Indeed,
L. iners is the prominent vaginal species following anti-
biotic treatment for BV [76]. Older studies aimed at de-
tecting BV, which could not differentiate Lactobacillus
species and concluded that it was BV rather than species
of Lactobacillus that conferred the risk.
Recent investigations into the protective role of Lacto-
bacillus species in the context of reproductive health
have revealed major species-specific differences in the
capacity to prevent pathobiont colonization and viral
infections [12, 72, 77, 78] that are driven largely by
maternal host-bacterial metabolite interactions at the va-
ginal mucosal interface. For example, although lactic
acid-producing bacteria including Lactobacillus spp.
produce both the D- and L-lactic acid isomers [79], the
chirality of the isomer has major functional implications.
In women exhibiting a vaginal microbiome dominated
by L. iners, an increased ratio of L to D-lactic acid has
previously been shown to promote expression of vaginal
extracellular matrix metalloproteinase inducer (EMM-
PRIN) and the activation of matrix metalloproteinase-8
(MMP8), which may subsequently modulate cervical in-
tegrity [80]. Conversely, no such relationship has been
observed in women with vaginal microbial communities
dominated by L. crispatus, which instead preferentially
excretes high levels of D-lactic acid and greater overall
levels of lactic acid than L. iners [80]. Apart from modu-
lating local tissue inflammation, recent studies have also
implicated lactate isomers in vaginal mucosal trapping
mechanisms. High concentrations of D-lactic acid are
associated with L. crispatus dominance and enhanced
trapping of HIV-1 virions in cervico-vaginal mucosa
whereas low concentrations of D-lactic acid associated
with L. iners dominance permits comparatively rapid dif-
fusion of virions through cervico-vaginal mucosa [77].
Collectively, these data suggest mechanisms by which L.
iners dominance of vaginal microbial communities dur-
ing pregnancy may lead to the modulation of local tissue
inflammation and remodeling pathways and to disrup-
tion of chemical and mechanical mucosal barriers pro-
tective against ascending infection and increase the risk
of preterm birth. Such mechanisms may account for the
observed association between L. iners dominance and a
short cervical length (<25 mm) seen in our study at
Fig. 3 Longitudinal profiling of community state types for
progesterone (n = 25) and control groups (n = 42). Progesterone
supplementation was commenced after the first sampling time
point (<18 weeks). Each longitudinal sample was assigned to a CST
(Fig. 1a) as indicated by the color-coded rectangle and categorized as
a function of delivery gestation
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16 weeks of gestation, which itself is highly specific for
preterm birth [81].
Considering the potential pro-inflammatory roles
played by L. iners in the vagina during pregnancy, we
postulated that any associated poor pregnancy outcomes
might be attenuated by the anti-inflammatory actions of
progesterone [45, 82]. However, in this study, no effect
of vaginal progesterone therapy upon the frequency of
vaginal community state structure was observed across
pregnancy indicating that the mode of action of proges-
terone in the prevention of preterm birth is not through
modulation of the vaginal microbiome. The data also
show, however, that there is no detrimental effect upon
the vaginal microbiome of either progesterone itself or
of the daily vaginal insertion of a pessary.
A particular strength of our study is that we character-
ized the vaginal microbiome in a comparatively large
patient cohort at high risk of preterm birth. This
strength was demonstrated by a high spontaneous pre-
term birth rate (n = 34/161). The mean gestation at birth
of 32+6 weeks within our preterm birth cohort, and a
distribution of gestational ages ranging from 24 to
36 weeks, enabled the characterization of microbial pro-
files associated with both early (<34 weeks) and late
(34 > 37 weeks) preterm birth, providing a broader
observational base for microbial-host interactions in
pregnancy. The primary limitation was the small number
of women receiving progesterone (n = 25) and the lack
of an equivalent control group with a short CL <25 mm
not receiving any intervention or receiving a placebo. A
short CL significantly increases subsequent preterm
birth risk [33]; therefore, once detected, clinicians are
ethically obliged to provide a preventative intervention
such as progesterone. Consequently, a “placebo” inter-
vention for a short cervix could not be included for
study in this clinical study. As such, the control women
are not true controls as their cervical lengths were all
greater than 25 mm at entry. A further potential con-
founding factor was the impact of ethnicity of vaginal
microbiota and gestation at birth, although we demon-
strated this not to be significant in our cohort.
Conclusions
Our data indicate that specific Lactobacillus species have
differing associations with outcome in pregnancies at
high risk of preterm birth. Detection of vaginal microbial
composition in the early second trimester may be used
to stratify preterm birth risk; L. crispatus dominance is
highly predictive of term birth, while high L. iners rela-
tive abundance is associated with increased risk of pre-
term birth and warrants heighted surveillance. Increased
diversity of vaginal microbiota at 16 weeks of gestation
is not associated with increased risk of preterm birth.
The use of progesterone therapy for preterm birth pre-
vention does not appear to adversely affect the relative
abundance of vaginal Lactobacillus species or species di-
versity, indicating that progesterone’s mode of action
during pregnancy is likely not via modulation of vaginal
microbial communities. Patients and clinicians who may
be concerned about the “infection risk” associated with
the use of vaginal pessaries during high-risk pregnancy
can be reassured.
Fig. 4 Preterm birth, despite vaginal progesterone, is associated with L. iners dominance throughout pregnancy. Longitudinal sampling of 25
women receiving progesterone for a short cervix showed L. iners dominance was associated with all women who subsequently delivered
preterm <34+0 weeks (n = 4; (**P < 0.05; Fisher’s exact). Single asterisk indicates the delivery samples collected within 2 weeks of delivery between
28 and 34 weeks
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